About: Preparation and development of equine hyperimmune globulin F(ab′)(2) against severe acute respiratory syndrome coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Preparation and development of equine hyperimmune globulin F(ab′)(2) against severe acute respiratory syndrome coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Preparation and development of equine hyperimmune globulin F(ab′)(2) against severe acute respiratory syndrome coronavirus
Creator	Guo, Zhong-Min Lu, Jia-Hai Zhong, Nan-Shan Zhang, Ding-Mei Zheng, Huan-Ying Wang, Yi-Fei Han, Wen-Yu Sun, Sheng-Yun Wang, Guo-Ling Wong, Bing Yang, Qin-He
Source	Medline; PMC
abstract	AIM: The resurgence of severe acute respiratory syndrome (SARS) is still a threat because the causative agent remaining in animal reservoirs is not fully understood, and sporadic cases continue to be reported. Developing high titers of anti-SARS hyperimmune globulin to provide an alternative pathway for emergent future prevention and treatment of SARS. METHODS: SARS coronavirus (CoV)F69 (AY313906) and Z2-Y3 (AY394989) were isolated and identified from 2 different Cantonese onset SARS patients. Immunogen was prepared from SARS-CoV F69 strain. Six health horses were immunized 4 times and serum was collected periodically to measure the profile of specific IgG and neutralizing antibodies using indirect enzyme-linked immunosorbent assay and a microneutralization test. Sera were collected in large amounts at the peak, where IgG was precipitated using ammonium sulphate and subsequently digested with pepsin. The product was then purified using anion-exchange chromatography to obtain F(ab′)(2) fragments. RESULTS: The specific IgG and neutralizing antibody titers peaked at approximately week 7 after the first immunization, with a maximum value of 1:14210. The sera collected at the peak were then purified. Fragment of approximately 15 g F(ab′)(2) was obtained from 1 litre antiserum and the purity was above 90% with the titer of 1:5120, which could neutralize the other strain (SARS-CoV Z2-Y3) as well. CONCLUSION: This research provides a viable strategy for the prevention and treatment of SARS coronavirus infection with equine hyperimmune globulin, with the purpose of combating any resurgence of SARS.
has issue date	2005-12-01(xsd:dateTime)
bibo:doi	10.1111/j.1745-7254.2005.00210.x
bibo:pmid	16297347
has license	no-cc
sha1sum (hex)	fcf3b31d9e7ba0d393bed6e674c8780f146692ed
schema:url	https://doi.org/10.1111/j.1745-7254.2005.00210.x
resource representing a document's title	Preparation and development of equine hyperimmune globulin F(ab′)(2) against severe acute respiratory syndrome coronavirus
has PubMed Central identifier	PMC7091834
has PubMed identifier	16297347
schema:publication	Acta Pharmacol Sin
resource representing a document's body	covid:fcf3b31d9e7ba0d393bed6e674c8780f146692ed#body_text
is schema:about of	named entity 'titer' named entity 'future' named entity 'specific' named entity 'litre' named entity 'IgG' named entity 'The' named entity 'TO MEASURE' named entity 'strategy' named entity 'Cantonese' named entity 'emergent' named entity 'Immunogen' named entity 'Sera' named entity 'isolated' named entity 'neutralizing antibodies' named entity 'peak' named entity 'antiserum' named entity 'IgG' named entity 'Conclusion' named entity 'SARS coronavirus' named entity 'ammonium' named entity 'purified' named entity 'titers' named entity 'pepsin' named entity 'antiserum' named entity 'IgG' named entity 'SARS-CoV' named entity 'causative agent' named entity 'neutralizing antibody' named entity 'hyperimmune globulin' named entity 'alternative pathway' named entity 'SARS' named entity 'microneutralization' named entity 'infection' named entity 'equine' named entity 'serum' named entity 'IgG' named entity 'severe acute respiratory syndrome coronavirus' named entity 'antisera' named entity 'inoculated' named entity 'pH 9' named entity 'minimum essential medium' named entity 'neutralizing antibodies' named entity 'protein' named entity 'SARS-CoV' named entity 'titer' named entity 'endotoxin' named entity 'pH 8' named entity 'IgG antibody' named entity 'Southeast Asia' named entity 'IgG' named entity 'IgG antibody' named entity 'pepsin' named entity 'kidney' named entity 'polio' named entity 'virus' named entity 'SARS-CoV' named entity 'SARS-CoV' named entity 'Immunoglobulin' named entity 'neutralizing antibodies' named entity 'Reed-Muench method' named entity 'Horseradish peroxidase' named entity 'vaccine' named entity 'anion-exchange chromatography' named entity 'vaccines' named entity 'virus' named entity 'IgG antibodies' named entity 'immunization' named entity 'SARS' named entity 'neutralizing antibodies' named entity 'SARS-CoV' named entity 'Laemmli'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software